As it has been shown that wild-type astrocytes can restore some function to MeCP2-deficient mice these findings have the potential to advance new therapeutic interventions targeting astrocytes for the treatment of Rett syndrome. The gene discussed is MECP2; the disease is atypical Rett syndrome.